 Connection
Everett Meyer to Female
This is a "connection" page, showing publications Everett Meyer has written about Female.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.190 |
|
|
|
-
Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CT, Villar-Prados A, Ji X, Jensen KP, Negrin RS, Meyer EH. Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy. Blood. 2026 05 21; 147(21):2489-2502.
Score: 0.033
-
Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177.
Score: 0.033
-
Meyer EH, Pavlova A, Villar-Prados A, Bader C, Xie B, Muffly L, Kim P, Sutherland K, Bharadwaj S, Dahiya S, Frank M, Arai S, Johnston L, Miklos D, Rezvani A, Shiraz P, Sidana S, Shizuru J, Weng WK, Agrawal V, Putnam A, Fernhoff N, Tamarisis J, Lu Y, Pawar RD, McClellan JS, Lowsky R, Negrin RS. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025 May 01; 145(18):2012-2024.
Score: 0.031
-
Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B, Tang SW, Baker J, Armstrong R, Tate K, Tadisco C, Arai S, Johnston L, Lowsky R, Muffly L, Rezvani AR, Shizuru J, Weng WK, Sheehan K, Miklos D, Negrin RS. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight. 2019 05 16; 4(10).
Score: 0.020
-
Narayan R, Benjamin JE, Shah O, Tian L, Tate K, Armstrong R, Xie BJ, Lowsky R, Laport G, Negrin RS, Meyer EH. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 07; 25(7):1293-1303.
Score: 0.020
-
Meyer EH, Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL, Strober S, Lavori P, Miklos DB, Johnson DS, Negrin RS. A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood. 2013 Jun 13; 121(24):4955-62.
Score: 0.013
-
Wang L, Pulgrossi RC, Anderson J, Garcia A, Meyer EH, Zehnder JL, Pinsky BA. Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients. J Appl Lab Med. 2026 Mar 05; 11(2):257-268.
Score: 0.008
-
Bharadwaj S, Lau E, Hamilton MP, Goyal A, Srinagesh H, Jensen A, Lee D, Mallampet J, Elkordy S, Syal S, Patil S, Latchford T, Sahaf B, Arai S, Johnston LJ, Lowsky R, Negrin R, Rezvani AR, Shizuru J, Meyer EH, Shiraz P, Mikkilineni L, Weng WK, Smith M, Sidana S, Muffly L, Maecker HT, Frank MJ, Mackall C, Miklos D, Dahiya S. Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. J Immunother Cancer. 2024 Jul 01; 12(7).
Score: 0.007
-
Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. J Exp Med. 2020 09 07; 217(9).
Score: 0.006
-
Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019 08 27; 3(16):2454-2464.
Score: 0.005
-
Schneidawind D, Baker J, Pierini A, Buechele C, Luong RH, Meyer EH, Negrin RS. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality. Blood. 2015 May 28; 125(22):3491-500.
Score: 0.004
-
Schneidawind D, Pierini A, Alvarez M, Pan Y, Baker J, Buechele C, Luong RH, Meyer EH, Negrin RS. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. Blood. 2014 Nov 20; 124(22):3320-8.
Score: 0.004
-
Sanchez Rodriguez R, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW, Yang SH, Anthony BA, Sverdrup FM, Krow-Lucal E, MacKenzie TC, Johnson DS, Meyer EH, Löhr A, Hsu A, Koo J, Liao W, Gupta R, Debbaneh MG, Butler D, Huynh M, Levin EC, Leon A, Hoffman WY, McGrath MH, Alvarado MD, Ludwig CH, Truong HA, Maurano MM, Gratz IK, Abbas AK, Rosenblum MD. Memory regulatory T cells reside in human skin. J Clin Invest. 2014 Mar; 124(3):1027-36.
Score: 0.004
-
Akbari O, Stock P, Meyer EH, Freeman GJ, Sharpe AH, Umetsu DT, DeKruyff RH. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol. 2008 Apr 15; 180(8):5448-56.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|